Description: Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.
Home Page: www.kitovpharma.com
One Azrieli Center
Tel Aviv,
6701101
Israel
Phone:
972 3 933 3121
Officers
| Name | Title |
|---|---|
| Mr. Isaac Israel | CEO & Director |
| Mr. Gil Efron CPA | Deputy CEO & CFO |
| Mr. Avraham Shlomo Ben-Tzvi | Group Chief Legal Officer, Gen. Counsel & Corp. Sec. |
| Mr. Simcha Rock CPA, M.B.A., CPA, MBA | Strategic Advisor & Director |
| Dr. Bertrand C. Liang | Chief Medical Officer |
| Dr. Michael Schickler | Head of Clinical Operations |
Exchange: TA
Country: IL : Israel
Currency: Israeli Agora (ILA)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2684 |
| Price-to-Sales TTM: | 16.3601 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |